Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial

Claudia Trenkwalder, Mikko Kuoppamäki, Mikko Vahteristo, Thomas Müller, Juha Ellmén, Claudia Trenkwalder, Mikko Kuoppamäki, Mikko Vahteristo, Thomas Müller, Juha Ellmén

Abstract

Objective: To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve "off" time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period.

Methods: This was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD.

Results: One hundred seventeen patients were randomized into the study (mean age 67.0 years; daily "off" time 5.3 hours; mean daily levodopa dose 610 mg). Carryover-adjusted mean changes from baseline "off" times were during ODM-101/65, -1.53 hours (p = 0.02 vs LCE), during ODM-101/105, -1.57 hours (p = 0.01 vs LCE), and during LCE -0.91 hours. Changes in daily "on" time without dyskinesia were 1.54 hours (p = 0.005 vs LCE), 1.38 hours (p = 0.0214 vs LCE), and 0.69 hours, respectively. Changes in "on" time with troublesome dyskinesia were <0.1 hours and not significantly different between treatments. In patients with high-activity COMT genotypes Val/Met or Val/Val, "off" time was reduced more with ODM-101/65 and ODM-101/105 than with LCE (p = 0.015 and p = 0.006). No difference between the treatments was seen in safety and tolerability. The most common treatment-related adverse effects were nausea, dizziness, drug-effect decrease, and dyskinesia, which were in most cases mild or moderate in severity. Treatment-related serious adverse events were diarrhea (ODM-101/105 and LCE), and myocardial ischemia and blood creatine kinase increase (LCE).

Conclusion: Increasing the dose of carbidopa in combination with levodopa and entacapone should be considered in the treatment of fluctuating PD to improve daily "off" times. Genotyping patients with PD according to COMT activity may improve individual treatment strategies.

Clinicaltrialsgov identifier: NCT01766258.

Classification of evidence: This study provides Class II evidence that an increased dose of carbidopa improves motor fluctuations when administered with levodopa and entacapone.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Study participant disposition and treatment…
Figure 1. Study participant disposition and treatment allocations
AE = adverse event; LCE = levodopa/carbidopa/entacapone.
Figure 2. Effect of carbidopa increase on…
Figure 2. Effect of carbidopa increase on “off” and “on” times
(A) Mean changes (−SEM) from baseline in daily “off” time. (B) Mean changes (+SEM) from baseline in daily “on” time without dyskinesia. 65 mg = ODM-101/65; 105 mg = ODM-101/105; LCE = levodopa/carbidopa/entacapone.

References

    1. Gershanik OS. Improving L-dopa therapy: the development of enzyme inhibitors. Mov Disord 2015;30:103–113.
    1. Cedarbaum JM, Kutt H, Dhar AK, Watkins FH, McDowell FH. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 1986;9:153–159.
    1. Kaakkola S, Männistö PT, Nissinen E, Vuorela R, Mäntylä R. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 1985;72:385–391.
    1. Hoehn MM. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. Arch Neurol 1980;37:146–149.
    1. Tourtellotte WW, Syndulko K, Potvin AR, Hirsch SB, Potvin JH. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease. Arch Neurol 1980;37:723–726.
    1. Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord 2012;27:750–753.
    1. Sweetman SC, editor. Martindale: The Complete Drug Reference. London: Pharmaceutical Press; 2011:893.
    1. Männistö P, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317–323.
    1. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997;42:747–755.
    1. Fox SH, Katzenschlager R, Lim SY, et al. . The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26:S2–S41.
    1. Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. . The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011;69:111–118.
    1. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
    1. Williams EJ. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Sci Res 1949;2:149–168.
    1. Hauser RA, Friedlander J, Zesiewicz TA, et al. . A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75–81.
    1. Senn SJ. Cross-over Trials in Clinical Research. Chichester: Wiley; 1993.
    1. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283–296.
    1. Hauser RA, Ellenbogen AL, Metman LV, et al. . Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011;26:2246–2252.
    1. Hauser RA, Hsu A, Kell S, et al. . Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346–356.
    1. Ferreira JJ, Rocha JF, Falcão A, et al. . Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. Eur J Neurol 2015;22:815–825.
    1. Ferreira JJ, Lees A, Rocha JF, et al. . Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 2016;15:154–165.
    1. Tolosa ES, Martin WE, Cohen HP, et al. . Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 1975;25:177–183.
    1. Kuoppamäki M, Korpela K, Marttila R, et al. . Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009;65:443–455.
    1. Kaakkola S, Teräväinen H, Ahtila S, et al. . Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995;2:341–347.
    1. Kuoppamäki M, Vahteristo M, Ellmén J, et al. . Pooled analysis of phase III with entacapone in Parkinson's disease. Acta Neurol Scand 2014;130:239–247.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner